Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Clinical trial NCT01646021 · COMPLETED
Trial details
- NCT number
- NCT01646021
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-12-10
- Primary completion
- 2015-06-05
- Enrollment
- 280
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.